ZEVALIN Kit for radiopharmaceutical preparations for infusion Ref.[11002] Active ingredients:

Source: European Medicines Agency (EU)  Revision Year: 2020  Publisher: Ceft Biopharma s.r.o., Trtinova 260/1, Cakovice, 196 00 Praha 9, Czech Republic

Product name and form

Zevalin 1.6 mg/ml kit for radiopharmaceutical preparations for infusion.

Pharmaceutical Form

Kit for radiopharmaceutical preparations for infusion.

Ibritumomab tiuxetan vial: Clear colourless solution.

Sodium acetate vial: Clear colourless solution.

Formulation buffer vial: Clear yellow to amber coloured solution.

Qualitative and quantitative composition

Zevalin is supplied as a kit for the preparation of yttrium-90 radiolabelled ibritumomab tiuxetan. The kit contains one ibritumomab tiuxetan vial, one sodium acetate vial, one formulation buffer vial, and one empty reaction vial. The radionuclide is not part of the kit.

One ibritumomab tiuxetan vial contains 3.2 mg ibritumomab tiuxetan* in 2 ml solution (1.6 mg per ml).

* murine IgG1 monoclonal antibody produced by recombinant DNA technology in a Chinese hamster ovary (CHO) cell line and conjugated to the chelating agent MX-DTPA.

The final formulation after radiolabelling contains 2.08 mg ibritumomab tiuxetan [90Y] in a total volume of 10 ml.

Excipients: This medicinal product can contain up to 28 mg sodium per dose, depending on the radioactivity concentration. To be taken into consideration by patients on a controlled sodium diet.

For the full list of excipients, see section 6.1.

List of Excipients

Ibritumomab tiuxetan vial:

Sodium chloride
Water for injections

Sodium acetate vial:

Sodium acetate
Water for injections

Formulation buffer vial:

Disodium phosphate dodecahydrate
Human albumin solution
Hydrochloric acid, diluted (for pH adjustment)
Pentetic acid
Potassium chloride
Potassium dihydrogen phosphate
Sodium chloride
Sodium hydroxide
Water for injections

Pack sizes and marketing

Zevalin is supplied as a kit for the preparation of yttrium-90 (90Y) radiolabelled ibritumomab tiuxetan.

Zevalin contains 1 of each of the following:

Ibritumomab tiuxetan vial: type I glass vial with a rubber stopper (teflon-lined bromobutyl) containing 2 ml solution.

Sodium acetate vial: type I glass vial with a rubber stopper (teflon-lined bromobutyl) containing 2 ml solution.

Formulation buffer vial: type I glass vial with a rubber stopper (teflon-lined bromobutyl) containing 10 ml solution.

Reaction vial: type I glass vial with a rubber stopper (teflon-lined bromobutyl)

Pack size of 1 kit.

Marketing authorization holder

Ceft Biopharma s.r.o., Trtinova 260/1, Cakovice, 196 00 Praha 9, Czech Republic

Marketing authorization dates and numbers

EU/1/03/264/001

Date of first authorisation: 16 January 2004

Date of latest renewal: 16 January 2009

Drugs

Drug Countries
ZEVALIN Austria, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Italy, Japan, Lithuania, Poland, United Kingdom, South Africa

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.